Survey on the Initiation of Aripiprazole Once-Monthly via a Two-Injection Start in Adult Patients with Schizophrenia: Experience of European Healthcare Professionals

• DOI: 10.1007/s12325-025-03130-w
• Publication Date: 2025-03-03T02:06:35Z
• Authors: Andrea Fagiolini; Karolina Leopold; Sofia Pappa; William J. Cottam; Joe Hickey; Olivia Rogerson; Murat Yildirim; Clodagh Beckham
• Keywords: Aripiprazole; Health Professionals

Aripiprazole once-monthly 400 mg (AOM 400) is a long-acting injectable (LAI) for the maintenance treatment of adults with schizophrenia. The AOM two-injection start initiation regimen 400-TIS) an alternative to one injection plus 14 days oral aripiprazole supplementation. This survey investigated real-world experiences European healthcare professionals (HCPs) 400-TIS. Physicians and nurses in Germany, Italy, United Kingdom who had prescribed and/or administered 400-TIS ≥ 3 times patients schizophrenia were invited participate online survey. primary objective was investigate HCPs' satisfaction Descriptive analysis performed on data collected between 1 February 21 March 2024. Data from 94 HCPs analysed. Most psychiatrists (62.8%) or psychiatric (29.8%) worked specialist mental health clinics/centres (59.6%) hospitals (inpatient, 36.2%; outpatient, 23.4%). Median duration clinical practice 21.0 years. Common reasons initiating poor adherence (85.1%), relapse (59.6%), high hospitalisation rates (48.9%). prescribing goals included improving (70.2%), preventing relapses (69.1%), patient quality life (62.8%). Barriers not wanting two injections (66.0%), tolerability concerns (30.9%), safety regarding administration dose single day (28.7%). Key factors influencing prescription prior (55.3%) efficacy agreed/strongly agreed that easy administer (79.8%) similar safety/tolerability profile one-injection majority satisfied outcomes (84.0%). reported administer, well tolerated, improved outcomes. its use reluctance perceived concerns.